Sibold continued, "These milestones reflect a clear and deliberate strategy: to secure Madrigal's long-term leadership in MASH. We're building a company with the potential to lead in this space for decades – and we plan to do so by scaling Rezdiffra across fibrosis stages and geographies, advancing a pipeline of complementary therapies, and delivering sustained value for patients, providers, and shareholders." Second-Quarter 2025 and Recent Corporate Updates • New U.S. Rezdiffra patent extends patent protec ...